DK1750716T3 - Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin - Google Patents

Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin

Info

Publication number
DK1750716T3
DK1750716T3 DK05756183T DK05756183T DK1750716T3 DK 1750716 T3 DK1750716 T3 DK 1750716T3 DK 05756183 T DK05756183 T DK 05756183T DK 05756183 T DK05756183 T DK 05756183T DK 1750716 T3 DK1750716 T3 DK 1750716T3
Authority
DK
Denmark
Prior art keywords
cell lymphoma
deazaaminopterin
propargyl
treatment
amount
Prior art date
Application number
DK05756183T
Other languages
English (en)
Inventor
Owen A O'connor
Francis Sirotnak
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1750716(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of DK1750716T3 publication Critical patent/DK1750716T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK05756183T 2004-05-30 2005-05-31 Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin DK1750716T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52159304P 2004-05-30 2004-05-30
PCT/US2005/019169 WO2005117891A1 (en) 2004-05-30 2005-05-31 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Publications (1)

Publication Number Publication Date
DK1750716T3 true DK1750716T3 (da) 2008-12-08

Family

ID=34971703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05756183T DK1750716T3 (da) 2004-05-30 2005-05-31 Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin

Country Status (24)

Country Link
US (4) US7939530B2 (da)
EP (1) EP1750716B1 (da)
JP (1) JP5005532B2 (da)
KR (1) KR101189693B1 (da)
CN (2) CN1960734A (da)
AT (1) ATE405272T1 (da)
AU (1) AU2005249516B2 (da)
BR (1) BRPI0510895A (da)
CA (1) CA2565968C (da)
DE (1) DE602005009176D1 (da)
DK (1) DK1750716T3 (da)
ES (1) ES2313365T3 (da)
HK (1) HK1177901A1 (da)
HR (1) HRP20080569T3 (da)
ME (1) ME01087B (da)
MX (1) MXPA06013559A (da)
NO (1) NO337276B1 (da)
NZ (2) NZ551082A (da)
PL (1) PL1750716T3 (da)
PT (1) PT1750716E (da)
RS (1) RS50622B (da)
SI (1) SI1750716T1 (da)
WO (2) WO2005117892A1 (da)
ZA (1) ZA200609266B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8263354B2 (en) * 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
SI1750716T1 (sl) * 2004-05-30 2009-06-30 Sloan Kettering Inst Cancer Zdravljenje t-celiäśnega limfoma z uporabo 10-propargil-10-deazaaminopterina
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
CA2853992C (en) 2007-07-31 2020-06-23 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US20090048262A1 (en) * 2007-08-17 2009-02-19 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
CA2729622C (en) 2008-07-03 2017-07-25 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
AU2010345065B2 (en) 2010-02-02 2014-06-05 Allos Therapeutics, Inc. Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same
WO2011153368A1 (en) * 2010-06-02 2011-12-08 Allos Therapeutics, Inc. Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin
RU2013102373A (ru) * 2010-08-10 2014-09-20 Аллос Терапьютикс, Инк. Продления выживаемости без прогрессирования заболевания с применением 10-пропаргил-10-деазааминоптерина
WO2013164856A1 (en) 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
CN103274943B (zh) * 2013-05-24 2015-01-21 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法
JP2018517788A (ja) 2015-06-16 2018-07-05 スペクトラム・ファーマシューティカルズ，インコーポレイテッド リンパ腫を治療するためにベリノスタットおよびプララトレキサートを使用する組合せ療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en) 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
ES2181734T3 (es) 1990-11-20 2003-03-01 Dade Behring Marburg Gmbh Ensayo inmunologico de ciclosporina.
US5354751A (en) 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
EP2258702A3 (en) * 1996-07-17 2011-11-30 Sloan-Kettering Institute For Cancer Research Purified compositions of 10-Propargyl-10-Deazaaminopterin and method of using same in the treatment of tumors
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
SI1750716T1 (sl) 2004-05-30 2009-06-30 Sloan Kettering Inst Cancer Zdravljenje t-celiäśnega limfoma z uporabo 10-propargil-10-deazaaminopterina

Also Published As

Publication number Publication date
SI1750716T1 (sl) 2009-06-30
DE602005009176D1 (de) 2008-10-02
WO2005117892A1 (en) 2005-12-15
PL1750716T3 (pl) 2009-01-30
US20050267117A1 (en) 2005-12-01
US20130053391A1 (en) 2013-02-28
CN1960734A (zh) 2007-05-09
CA2565968A1 (en) 2005-12-15
WO2005117891A1 (en) 2005-12-15
US7939530B2 (en) 2011-05-10
ME01087B (me) 2012-12-20
KR20110081327A (ko) 2011-07-13
ZA200609266B (en) 2008-12-31
AU2005249516A1 (en) 2005-12-15
AU2005249516B2 (en) 2010-11-18
CN102824346A (zh) 2012-12-19
NO20065971L (no) 2006-12-22
JP5005532B2 (ja) 2012-08-22
MXPA06013559A (es) 2007-04-24
JP2008501038A (ja) 2008-01-17
CA2565968C (en) 2013-01-08
ATE405272T1 (de) 2008-09-15
KR101189693B1 (ko) 2012-10-10
NZ551082A (en) 2009-06-26
HRP20080569T3 (en) 2008-12-31
RS50622B (sr) 2010-06-30
US7622470B2 (en) 2009-11-24
US20080058280A1 (en) 2008-03-06
ES2313365T3 (es) 2009-03-01
EP1750716A1 (en) 2007-02-14
PT1750716E (pt) 2008-11-04
CN102824346B (zh) 2015-04-22
HK1177901A1 (en) 2013-08-30
BRPI0510895A (pt) 2007-11-27
US20100120777A1 (en) 2010-05-13
EP1750716B1 (en) 2008-08-20
NO337276B1 (no) 2016-02-29
NZ576849A (en) 2011-03-31
US8299078B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
DK1750716T3 (da) Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
NO20014519D0 (no) Apomorfin- og sildenafilpreparat
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
BRPI0517976A (pt) métodos de tratamento
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
RU2013123646A (ru) Комбинированная композиция
DK1485051T3 (da) Fremgangsmåde til indgivelse af buprenorphin til behandling af depression
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
CY1118486T1 (el) Λαπατινιμπη για τη θεραπεια του καρκινου
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
RU2009101026A (ru) Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
RU2005114664A (ru) Способ лечения хронического панкреатита
TW200626172A (en) Treatment of HIV infection
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations
WO2007093519A3 (en) Ibandronate regimen for treating metastatic bone pain
UA3797U (uk) Спосіб лікування тяжких проникаючих поранень ока